Recruiting A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity NCT07100210 Conditions Interleukin, Refractory Malignant Solid Tumors, mRNA Vaccine Locations West China Hospital of Sichuan University — Chengdu, Sichuan, China View Trial Details
Completed Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors. NCT07040943 Conditions Interleukin, Refractory Malignant Solid Tumors, mRNA Vaccine Locations Department of Radiation Oncology — Chengdu, Sichuan, China West China Hospital of Sichuan University — Chengdu, Sichuan, China View Trial Details
